Related Experiment Video

Updated: Aug 15, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Treatment of hepatitis C in special populations

Cynthia A Moylan1, Andrew J Muir

  • 1Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Box 3913, Durham, NC 27710, USA.

Clinics in Liver Disease
|October 7, 2005
PubMed

Insights

New hepatitis C virus (HCV) treatments show promise, but research is needed for specific populations like African Americans and those with HIV or kidney disease. This review examines recent findings and future directions for HCV treatment in these groups.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Clinical Research

Background:

  • Hepatitis C virus (HCV) treatment options have advanced significantly.
  • Current recommendations stem from trials with select patient groups.
  • HCV disproportionately affects African Americans, and individuals with HIV, end-stage renal disease, and hemophilia.

Purpose of the Study:

  • To review recent research findings on HCV treatment in underrepresented patient populations.
  • To examine the current state of HCV treatment for African Americans, and patients with HIV, ESRD, and hemophilia.
  • To explore future directions and ongoing clinical trials for HCV management in these groups.

Main Methods:

  • Literature review of recent research studies.
  • Analysis of clinical trial data concerning specific patient cohorts.
  • Synthesis of findings related to HCV treatment efficacy and challenges.

Main Results:

  • HCV prevalence and treatment outcomes vary across different patient demographics.
  • Specific challenges exist in treating HCV in patients with comorbidities like HIV and ESRD.
  • Emerging research highlights the need for tailored treatment strategies.

Conclusions:

  • Further research is crucial to optimize HCV treatment for diverse populations.
  • Clinical trials must include broader patient groups to inform effective guidelines.
  • Personalized approaches are essential for improving HCV outcomes in vulnerable populations.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...